Price T Rowe Associates Inc Blueprint Medicines Corp Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BPMC
# of Institutions
336Shares Held
62MCall Options Held
987KPut Options Held
578K-
Black Rock Inc. New York, NY6.65MShares$554 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.54MShares$545 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.24MShares$270 Million0.06% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.46MShares$205 Million8.22% of portfolio
-
State Street Corp Boston, MA2.38MShares$198 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $4.98B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...